MINNEAPOLIS & NEW YORK--(BUSINESS WIRE)--An implantable medical device used in the minimally invasive treatment of thoracic aortic aneurysms, the Valiant® Thoracic Stent Graft System from Medtronic, Inc. (NYSE: MDT), delivered strong results through 30 days of patient follow-up in the company’s U.S. pivotal study, according to clinical data presented at VEITHsymposium™.
